Multiomics Manufacturers and Recent Developments
The global multiomics market size is calculated at US$ 2.76 in 2024, grew to US$ 3.18 billion in 2025, and is projected to reach around US$ 11.46 billion by 2034. The market is expanding at a CAGR of 15.32% between 2024 and 2034.
Top Companies in the Multiomics Market
- BD
- Thermo Fisher Scientific, Inc.
- Illumina, Inc
- Danaher (Beckman Coulter)
- PerkinElmer, Inc
- Shimadzu Corporation
- Bruker
- QIAGEN
- Agilent Technologies, Inc.
- BGI Genomics
Multiomics Market Trends
- In November 2024, the healthcare startup PrognomiQ, which is dedicated to using multi-omics data to revolutionize cancer and other complicated illness monitoring, early therapy selection, and identification, announced that it had raised $34 million in Series D funding.
- In February 2024, the biotechnology startup Freenome, which creates blood tests for early cancer diagnosis, reported that it had raised $254 million from both new and current investors. With the help of the funds, Freenome may further develop the pipeline of customized multi-cancer and single-cancer early detection tests based on its multiomics platform.
Latest Announcements by Industry Leaders
In October 2024, a strategic alliance was established between Singleton Biotechnologies, a pioneer in single-cell multi-omics solutions, and Bioscreen, a well-known distributor of cutting-edge life science products in India. This deal would make Bioscreen the only distributor of Singleron's state-of-the-art single-cell multi-omics products in India.
Recent Developments in the Multiomics Market
- In December 2024, one of the pioneers of high-definition spatial proteomics, Ionpath, announced the release of MIBIslide™ Blue, a revolutionary multimodal imaging tool.
- In July 2024, in order to support the ongoing development of its DNA sequencing and multi-omics technologies, Element Biosciences announced a Series D investment of more than $277 million.
- In February 2024, a £6.7 million fundraising round was announced by Tagomics, a University of Birmingham spinout that is creating a state-of-the-art platform for thorough illness understanding and diagnosis.
